| Jason Vaughn |
Jason Vaughn is currently the Senior Vice President-Technical Operations at Avadel Pharmaceuticals Plc. Prior to this, he held positions such as Director-Formulation Development at DPT Laboratories Ltd., Research Director at Emergent Technologies, Inc., Principal at Formulation Technologies LLC, Vice President-Process Technology Development at Patheon Pharmaceuticals, Inc., Vice President-Pharmaceutical Development at Banner Life Sciences LLC, and Principal at Wyatt Pharma Consulting LLC. Dr. Vaughn has a graduate degree from the University of Texas Medical Branch and undergraduate and doctorate degrees from the University of Texas at Austin. |
| Jennifer Gudeman |
Jennifer Gudeman is currently the Vice President-Medical & Clinical Affairs at Avadel Pharmaceuticals Plc since 2020. Prior to this, she worked as the Director-Medical Affairs at AMAG Pharma USA, Inc. and as the Vice President-Medical Affairs at AMAG Pharmaceuticals, Inc. Dr. Gudeman completed her undergraduate degree in 1999 and her doctorate degree in 2000 from St. Louis College of Pharmacy. |
| Richard J. Kim |
Richard J. Kim is currently the Chief Commercial Officer at Avadel Pharmaceuticals Plc since 2021. Prior to this, he worked as the President-U.S. Commercial & Strategic Marketing at Intercept Pharmaceuticals, Inc. from 2015 to 2021. He also worked as the General Manager at Bristol Myers Squibb Co. Mr. Kim completed his undergraduate degree from the University of Alberta. |
| Jerad G. Seurer |
Jerad G. Seurer is currently the Secretary, Compliance Officer & General Counsel at Avadel Pharmaceuticals Plc since 2017. Previously, he worked as the Group General Counsel-Generics/API Business at Mallinckrodt Pharmaceuticals Ltd. Mr. Seurer completed his undergraduate and graduate degrees at the University of South Dakota. |
| Geoffrey Michael Glass |
Geoffrey Michael Glass is the founder of ClearSciences LLC, which was founded in 2015. He held the title of President at ClearSciences LLC from 2015 to 2017. Mr. Glass is also the founder of Kiniciti. Mr. Glass's current job(s) include being the President, Chief Executive Officer & Director at Sancilio & Co., Inc. since 2018, and the Non-Executive Chairman at Avadel Pharmaceuticals Plc since 2018. Mr. Glass's former job(s) include being the Chief Executive Officer & Director at Sancilio Pharmaceuticals Co., Inc. from 2017 to 2018, Chairman at Abzena Ltd. in 2022, Director at Locus Biosciences, Inc. from 2015 to 2017, Senior Vice President-Asia Region at Bausch Health Americas, Inc. from 2004 to 2008, President-Products & Technology Commercialization at Patheon, Inc. from 2009 to 2014, Operating Partner at LongueVue Capital LLC, Executive Vice President-Sales & Marketing at Patheon Pharmaceuticals, Inc. in 2009, and President at Banner Life Sciences LLC from 2009 to 2012. Mr. Glass's education history includes an undergraduate degree from the University of Arizona. |
| Scott Macke |
Scott Macke is currently the Vice President of Supply Chain & Operations at Avadel Pharmaceuticals Plc since 2014. Prior to this, he worked as a Senior Director of Project Management at AMAG Pharma USA, Inc. Mr. Macke holds a Master's in Business Administration from Maryville University of St. Louis and an undergraduate degree from Missouri State University. |
| Thomas S. McHugh |
Thomas S. McHugh is currently the Chief Financial Officer & Senior Vice President at Avadel Pharmaceuticals Plc. Previously, he worked as the Managing Director & Controller at BearingPoint, Inc. and as the Chief Financial Officer, Treasurer, Director & CAO at K-V Generic Pharmaceuticals, Inc. He also served as the Chief Financial Officer, Treasurer & VP at AMAG Pharma USA, Inc. and as the Controller at XTRA Corp. In addition, he was the Chief Financial Officer at Huttig Building Products, Inc. and a Principal at Pricewaterhousecoopers LLC. He also worked as the Senior Vice President-Finance at Ironshore Pharmaceuticals (America), Inc. McHugh received his undergraduate degree from Bentley University and his graduate degree from Northeastern University. |
| Gregory J. Divis |
Gregory J. Divis is currently the Chief Executive Officer & Director at Avadel Pharmaceuticals Plc. He also holds positions as a Director at Mobius Therapeutics LLC, Health eVillages, Inc., President at Marchem Northeast, Inc., and Chief Commercial Officer & Executive VP at Avadel Management Corp. Previously, Dr. Divis served as the President & Chief Executive Officer at AMAG Pharma USA, Inc. from 2011 to 2013. He was also the President & Chief Executive Officer at Lumara Health Services Ltd. in 2014 and President, Chief Executive Officer & Director at K-V Generic Pharmaceuticals, Inc. from 2010 to 2014. Additionally, he held the position of Director at Accella Performance Materials, Inc. and Tolero Pharmaceuticals, Inc. from 2015 to 2017. Dr. Divis was an Independent Director at Jaguar Health, Inc. from 2018 to 2022. He worked at Schering-Plough Corp. as the Vice President & General Manager-UK & Ireland from 1992 to 2003. He also served as the President at RB Rubber Products, Inc. and as an Operating Partner at Linden Manager LLC in 2015 and 2016, respectively. Furthermore, he held the position of VP-Business Development & Life Cycle Management at Sanofi-Aventis U.S. LLC from 2004 to 2007 and was a Principal at Schering-Plough Ltd.Dr. Divis obtained his undergraduate degree from the University of Iowa in 1988. |
| Mark A. McCamish |
Mark A. McCamish is currently serving as the President, Chief Executive Officer & Director at IconOVir Bio, Inc. He is also an Independent Director at Avadel Pharmaceuticals Plc and Rafael Holdings, Inc. Previously, Dr. McCamish held the positions of President, Chief Executive Officer & Director at Forty Seven, Inc. from 2017 to 2020. He was also a Director at Abbott Laboratories in 1997. Additionally, he served as an Independent Director at Vincerx Pharma, Inc. from 2020 to 2021. Dr. McCamish has a background in academia, having worked as a Professor at The Ohio State University and the University of California, Davis. He also held the role of Chief Medical Officer & Senior Vice President at PDL BioPharma, Inc. from 2007 to 2008. In terms of education, Dr. McCamish obtained a doctorate degree from The Pennsylvania State University in 1980. He also holds undergraduate and graduate degrees from the University of California, Santa Barbara, and a doctorate degree from the David Geffen School of Medicine. |
| Peter J. Thornton |
Peter J. Thornton founded Oculer Ltd. in 2014, where he is working as Director from 2014. Mr. Thornton also currently works at Avadel Pharmaceuticals Plc, as Independent Director from 2017, Techno-path Manufacturing Ltd., as Chief Financial Officer from 2014, and Envetec Sustainable Technologies Ltd., as President & Chief Financial Officer. Mr. Thornton also formerly worked at CyDex Pharmaceuticals, Inc., as Director, Merrion Pharmaceuticals Plc, as Independent Non-Executive Director in 2011, Alkermes, Inc., as Senior Vice President-Business Integration from 2011 to 2013, Agenus, Inc., as Chief Financial Officer from 2004 to 2006, Circ Pharma Ltd., as President & Chief Operating Officer from 2006 to 2007, Alkermes Plc, as Senior Vice President-Business Integration, Elan Drug Technologies, as SVP-Corporate & Business Development from 2007 to 2011, and leon-nanodrugs GmbH, as Member-Supervisory Board. Mr. Thornton received his undergraduate degree from University College Cork. |
| Linda S. Palczuk |
Linda S. Palczuk is an Independent Director at Avadel Pharmaceuticals Plc and the Chief Operating Officer at Envara Health, Inc. She was previously the President & Chief Executive Officer at Osiris Therapeutics, Inc., Vice President-Sales & Marketing at AstraZeneca Pharmaceuticals LP, and Chief Operating Officer at Verrica Pharmaceuticals, Inc. Palczuk holds an undergraduate degree from Franklin & Marshall College and an MBA from Alfred Lerner College of Business & Economics. |
| Eric J. Ende |
Eric J. Ende is the founder of Wellfit Holdings LLC. He currently holds the position of Chairman at Matinas BioPharma Holdings, Inc. and Director at Matinas BioPharma, Inc. He is also a Director at Mesa Therapeutics, Inc. and an Independent Director at Avadel Pharmaceuticals Plc. In addition, he is the President of Ende Consulting Group, Inc. and Ende Biomedical Consulting Group, Inc. His former positions include being a Director at Amylin Pharmaceuticals, Inc., Progenics Pharmaceuticals, Inc., Genzyme Corp., and NeuBase Therapeutics, Inc. He also worked as a Research Analyst at Merrill Lynch, Pierce, Fenner & Smith, Inc. Dr. Ende obtained his undergraduate degree from Emory University in 1990. He holds an MBA from New York University and The Leonard N Stern School of Business, both conferred in 1997. He also earned a doctorate from the Icahn School of Medicine at Mount Sinai in 1994. |
